Regenerative Medicine of Raynham: A 2026 Patient Due-Diligence Guide

Patient reviewing questions before a consultation at Regenerative Medicine of Raynham

Regenerative Medicine of Raynham: A 2026 Patient Due-Diligence Guide

Introduction: What This Guide Is (and Isn’t)

This guide is an independent due-diligence resource. It is not an official profile, review, or endorsement of Regenerative Medicine of Raynham LLC or any other clinic. TopDoctor Magazine has no affiliation with the practice, and nothing here should be read as a judgment about the quality of its care.

Most people searching for this clinic have already heard the name through an advertisement, a referral from a friend, or a local search result. Many are now weighing whether to book a consultation. This guide is written for that stage, before any money changes hands.

It answers several core questions:

  • Is a chiropractor-led regenerative model legal in Massachusetts?
  • What do terms like “FDA 351 vs. 361,” “IRB oversight,” and “experimental use” actually mean for a patient?
  • How can a patient independently verify a clinic’s safety and legitimacy?

The same vetting framework applies to any regenerative medicine practice in Massachusetts or the wider New England region, not just this one.

Orienting Facts: Regenerative Medicine of Raynham at a Glance

Based on publicly available information, the basic details are:

  • Business name: Regenerative Medicine of Raynham LLC
  • Address: 575 South Street West, Ste 2B, Raynham, MA 02767
  • Phone: (774) 409-5055
  • Established: 2019
  • Leadership: Dr. Brian Petrie, DC, a chiropractor whose clinical work in the local community spans more than 30 years

The clinic markets a range of non-surgical modalities, including platelet-rich plasma (PRP), alpha-2-macroglobulin (A2M), shockwave therapy, laser therapy, pulsed electromagnetic field (PEMF) therapy, spinal and knee decompression, and metabolic or functional-medicine support. Its stated care pathway begins with an evaluation, followed by PRP, A2M, shockwave, laser, and decompression as indicated.

These facts are presented for identification purposes only. The remainder of this guide explains how patients can independently verify claims like these for any clinic.

The Massachusetts Regulatory Wrinkle: Why This State Is Different

In an April 2023 public meeting, the Massachusetts Board of Registration of Chiropractors voted that injections are not within the scope of practice for licensed chiropractors in Massachusetts.

This matters because PRP and A2M are injection-based treatments. Under the Board’s position, a chiropractor in a DC-led practice should not be the person who performs the injection itself.

This is a Massachusetts-specific nuance. Patients are unlikely to find it on Yelp, local directories, or in any clinic’s own marketing materials. Rules differ from state to state, and a model that is routine elsewhere may need a different structure here.

The practical implication is straightforward: any Massachusetts regenerative clinic headed by a chiropractor must involve a licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) to legally administer injections.

Understanding the Collaborative Physician-Oversight Model

Collaborative models are the common legal and clinical solution. In this arrangement, the chiropractor typically manages evaluation, treatment planning, and non-injection modalities such as shockwave, laser, and decompression. A licensed medical provider performs or directly supervises the injections.

Regenerative Medicine of Raynham’s own materials describe this type of structure. The clinic states that shockwave and related procedures are delivered by Dr. Petrie, DC, with medical oversight from Dr. David Cunningham, MD, and that its clinical team also includes Melissa Teixeira Palmer, DNP, NP-C.

Oversight on Paper vs. Oversight in Practice

“Medical oversight” can mean very different things. In a well-run practice, it typically includes:

  • Direct supervision of procedures
  • Formal credentialing of everyone who performs injections
  • Documented, written treatment protocols

At the other extreme, oversight can be nominal: a physician’s name on a website with little actual involvement. Patients cannot tell the difference from marketing copy alone.

Questions Patients Should Ask

  • Who physically performs the injection?
  • What is that person’s license type, and is the license currently active in Massachusetts?
  • Is the supervising physician on-site, or reachable in real time if something goes wrong?

This distinction matters for the patient, not only for the clinic’s liability. If a complication occurs, a patient needs to know which licensed professional was responsible, which board oversees that person, and where to turn for recourse.

Decoding FDA Product Classification: 351 vs. 361

The FDA sorts many human cell and tissue products into two broad categories, named for sections of the Public Health Service Act.

  • 361 products are minimally manipulated and intended for homologous use, meaning the tissue performs the same basic function in the patient as it did in its original location. These do not require FDA premarket approval.
  • 351 products are regulated as drugs or biologics. They require FDA approval, supported by clinical trials, before they can be legally marketed.

One key fact surprises many patients: the only FDA-approved stem cell products are certain blood-forming stem cells derived from umbilical cord blood. Nearly all orthopedic stem cell and PRP treatments operate under a provider’s clinical judgment, not a specific FDA approval for that use.

Courts have reinforced this distinction. In 2024, the U.S. Court of Appeals for the Ninth Circuit ruled that a clinic’s stromal vascular fraction (SVF) product was properly regulated as a drug, because the reinjected tissue was not intended to perform the same basic function as in its original site.

Classification matters to patients because it determines the level of oversight, the manufacturing standards that apply, and what a clinic can legally claim about safety and effectiveness.

Actionable tip: Patients should ask the clinic directly which classification (351 or 361) applies to the specific product being recommended, and request documentation.

“Observational Registry” and “Experimental Use” Language: What It Really Means

Some regenerative clinics describe their outcomes tracking as an “IRB-approved observational registry,” or frame certain treatments under an “experimental use model,” sometimes in connection with cartilage-defect studies. The Raynham clinic’s broader web materials reference both concepts.

These terms are often misunderstood:

  • An IRB-approved observational registry tracks the outcomes of a treatment that is already being offered. An Institutional Review Board reviews the ethics of collecting that data. It is not the same as an FDA-approved clinical trial designed to test safety and efficacy for approval.
  • “Experimental use” framing does not equal FDA endorsement, and it does not guarantee that a treatment works.

Questions to Ask

  • Which IRB approved this registry, and can the patient see the registration?
  • Is the patient enrolling in a trial, or is this outcomes tracking?
  • Is there any cost associated with “registry participation”?

Clear, documented answers are a strong green flag. Vague or evasive responses are a red flag.

What the Evidence Actually Shows: PRP vs. A2M

PRP

The evidence for PRP in knee osteoarthritis is comparatively mature:

  • A 2025 meta-analysis in the American Journal of Sports Medicine found that PRP produced statistically and clinically superior improvement compared with placebo at all follow-up points. High-platelet-concentration PRP showed more durable benefit than low-platelet PRP out to 12 months.
  • A 2025 narrative review of 40 high-quality studies found that PRP, especially leukocyte-poor PRP, outperformed hyaluronic acid and corticosteroids for mild-to-moderate knee osteoarthritis. However, differences in PRP formulations and protocols limit direct comparison across studies.

A2M

A2M evidence is at a much earlier stage. A 2025 narrative review notes that its anti-inflammatory and cartilage-protective effects have been demonstrated largely in preclinical, animal, and laboratory models. Human randomized trial data remain limited, such as a small NYU trial involving 75 patients.

Practical Takeaway

PRP has a more developed evidence base than A2M. Patients should ask any clinic to name the specific published studies that support the exact product and dosing protocol being recommended for their condition.

Cost and Insurance Reality Check

PRP and stem cell or orthobiologic injections are almost universally classified as “investigational.” As a result, they are not covered by most commercial insurance plans, Medicare, or Medicaid.

Self-pay, HSA/FSA funds, or financing arrangements are the norm. Patients should budget accordingly rather than expect reimbursement.

For context, national price ranges include:

Procedure Typical Range
PRP Roughly $500 to $3,500 per injection
Bone marrow concentrate, adipose, or birth-tissue procedures $3,000 to $12,000+

Red flags: high-pressure package pricing, required prepayment for multiple visits, or reluctance to itemize costs.

Green flags: clear, itemized pricing and written acknowledgment that insurance will not cover the treatment.

National Enforcement History: Why Scrutiny of This Industry Exists

Since 2017, the FDA has filed injunctions against two companies and issued at least 35 regulatory letters to businesses marketing unapproved regenerative products.

The agency has documented serious harms from unapproved regenerative and stem cell products, including infections, blood clots, tumors and other growths, and organ damage. In one injunction case, an unproven stem cell product blinded one patient and severely damaged the vision of two others.

The Federal Trade Commission has separately warned consumers about deceptive stem cell marketing claims, a move publicly welcomed by the International Society for Stem Cell Research (ISSCR).

This history explains why regulators, journalists, and consumer advocates treat marketing in this space with elevated scrutiny. It is not an accusation against any specific clinic. It is necessary context for an informed decision.

State-Level Accountability: Attorneys General and Massachusetts Resources

Federal agencies are not the only enforcers. State Attorneys General in Washington, New York, Nebraska, and Georgia have sued regenerative and stem cell clinics under consumer protection and false-advertising laws for unsubstantiated claims. State-level enforcement is a live, independent layer of accountability.

Massachusetts residents have in-state resources:

  • Massachusetts Attorney General’s Consumer Advocacy & Response Division: the channel for filing complaints or researching consumer issues involving a provider.
  • Massachusetts Department of Public Health: state law requires any institution conducting human embryonic stem cell research in Massachusetts to obtain a Certificate of Registration. This is useful context when a clinic uses the term “stem cell.”
  • Massachusetts licensing boards: patients can verify license status for chiropractors, physicians, and nurse practitioners.

Checking these sources before committing to treatment takes little time and can prevent costly mistakes.

The New England Patient Due-Diligence Checklist

  1. Verification of who performs the injection, including confirmation of that person’s license type and current Massachusetts registration.
  2. Confirmation of the supervising physician’s name, license, and actual level of involvement (on-site vs. nominal).
  3. Clarification of whether the product is a 351 or 361 product, with supporting documentation requested.
  4. If a registry or IRB oversight is mentioned, identification of the IRB’s name and registration, and clarification of whether it is a trial or outcomes tracking.
  5. Specific study citations supporting the proposed treatment and product for the patient’s condition.
  6. Itemized pricing in writing, with confirmation that insurance will not cover the procedure.
  7. A check for prior complaints with the Massachusetts AG’s Consumer Advocacy & Response Division and the relevant licensing boards.
  8. A comparison against peer transparency benchmarks, such as a competing clinic’s public statements about FDA guideline compliance and its avoidance of “cure” claims.

Red Flags vs. Green Flags Summary

Red flags:

  • Vague answers about who performs injections
  • Refusal to name the supervising physician
  • Claims that a treatment is a “cure”
  • Pressure to prepay for multi-session packages
  • No written pricing
  • Inability to cite specific studies

Green flags:

  • Clear disclosure of physician oversight
  • Willingness to provide license numbers
  • Open discussion of FDA classification
  • Itemized pricing
  • Documented IRB approval if a registry is mentioned
  • Explicit statements that outcomes are not guaranteed

Conclusion: Making an Informed Decision

Regenerative medicine can offer legitimate benefit, and the PRP evidence in particular is relatively mature. Still, the industry’s regulatory landscape requires active diligence from patients.

Effective vetting rests on three pillars:

  1. Legal scope-of-practice compliance, especially Massachusetts’ rule on chiropractors and injections
  2. FDA product classification transparency
  3. Verifiable evidence and clear pricing

This framework applies to any Massachusetts or New England regenerative medicine provider, not only the clinic that prompted the search. Patients will get the most value by using the checklist as a guide for the consultation conversation rather than relying on marketing materials alone.

Next Steps: Research Before Booking

  • Patients should bring the checklist to any prospective clinic’s initial consultation and note how each question is answered.
  • Patients should cross-reference claims with the Massachusetts Board of Registration of Chiropractors, the Massachusetts AG’s consumer resources, and current FDA guidance before proceeding.
  • Patients can explore the national framework in TopDoctor Magazine’s evergreen resource, Regenerative Medicine Centers: 2026 Patient’s Guide, which covers FDA rules and additional vetting background.
  • Sharing this guide with family members or friends considering similar treatment can help. Informed patients make better decisions, and supporting those decisions is central to TopDoctor Magazine’s mission.

Related Posts